Creating Biomedical Technologies to Improve Health


FY 2018 Financial Management Plan

R01 19%1

10% reduction
Limited to 4 years

Expanded Opportunity Zone (EOZ) 38%2 Negotiated
Parent/ERBG R21 Select Pay3 No reduction
Trailblazer R21 Select Pay4 No reduction
R15, R03 19% No reduction
P41 Select Pay5 No reduction
U01 Select Pay5 10% reduction
Limited to 4 years
(BRP U01s-no reduction, limited to 5 years)
F32, F33, T32, K01, K08, K23, K24, K25, K99/R00, SBIR, STTR Select Pay6 No reduction


1 The percentile payline for new investigator R01 applications is 5% higher, i.e. 24%. See policy at

2 The Expand Opportunity Zone (EOZ) is approximated twice the payline. Applications within the EOZ may be selected for funding based on the criteria outlined at The EOZ for R01 and R03 applications is from the 20th to the 38th percentile. For new investigator applications, the EOZ is from the 25th to the 43rd percentile. 

3The NIBIB implemented a new policy for R21s beginning in FY17. As part of the new policy, R21 funding is based on programmatic considerations. See Guide Notice at Please note that for FY18 there is a new NIBIB R21 FOA at which has replaced NIBIB participation on the Parent R21 FOA ( and the EBRG FOA

4The NIBIB Trailblazer R21 is a new initiative for New and Early Stage Investigators. Trailblazer funding is based on programmatic considerations.  Read more at

5No fixed payline exists for P41 and U01 awards. Applications are considered on a case-by-case basis based on programmatic considerations. Bioengineering Research Partnership (BRP) U01s do not receive any administrative cuts.

6No fixed payline exists for F, K, T32, SBIR and STTR grants. A limited number of awards are available for highly meritorious applications. Funding decisions are also based on programmatic considerations and available funds.